Allgens(688613)2023-04-20 16:00Financial Performance - In 2022, the company's operating revenue was CNY 245.31 million, representing a year-on-year increase of 3.92%[21]. - The net profit attributable to shareholders was CNY 95.22 million, a decrease of 21.17% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 80.06 million, down 17.86% year-on-year[24]. - The net cash flow from operating activities decreased by 21.35% to CNY 102.05 million[24]. - Total assets increased by 2.32% year-on-year, reaching CNY 1.46 billion[24]. - The basic earnings per share decreased by 29.7% to CNY 0.71[22]. - The weighted average return on net assets dropped to 7.37%, a decrease of 9.82 percentage points compared to the previous year[23]. - The company reported quarterly revenues of CNY 45.89 million, CNY 58.45 million, CNY 71.63 million, and CNY 69.34 million for Q1 to Q4 respectively[26]. Research and Development - The R&D expenditure as a percentage of operating revenue rose to 23.42%, an increase of 9.34 percentage points from the previous year[23]. - In 2022, the company invested CNY 57.46 million in R&D, accounting for 23.42% of its revenue[35]. - The company achieved significant progress in its product pipeline, with two projects entering clinical trial stages, including collagen protein sponge and mineralized collagen/polyester artificial bone repair materials[35]. - The company was granted 9 invention patents by the National Intellectual Property Administration of China, bringing the total to 54 patents by the end of the reporting period[36]. - The company published 3 academic papers and released an academic monograph titled "Biomimetic Materials for Biomedical Applications" in October 2022[36]. - The company’s core technologies include biomimetic mineralization technology and collagen extraction and purification technology, all of which are proprietary innovations[60]. - The company is involved in a national key R&D project focused on new generation biomimetic mineralized collagen implants, which is progressing as planned[62]. Market Expansion and Sales - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24]. - In 2022, the company added over 150 distributors and developed more than 200 new hospitals, resulting in a positive sales trend and stable growth in its main business[37]. - The company primarily generates revenue through the sale of mineralized collagen artificial bone repair materials to distributors and hospitals[42]. - The company has expanded its product line to cover all provinces, cities, and autonomous regions in China, with over 200 new terminal hospitals added during the reporting period, receiving unanimous recognition from clinical experts[51]. - The company is focusing on optimizing the characteristics of scaffold materials and advancing the theoretical framework and product design of bone tissue engineering for future development of artificial bone repair materials[47]. Governance and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company has established a comprehensive internal control system to ensure effective business operations and compliance with regulatory requirements[39]. - The company has received a standard unqualified audit report from its accounting firm[5]. - The company completed the election of its second board of directors and supervisory board on November 29, 2022[34]. Employee and Management - The company has a structured employee compensation system based on job responsibilities, performance, and market competitiveness[173]. - The employee compensation structure includes basic salary, position salary, performance salary, and bonuses, ensuring a comprehensive approach to employee remuneration[173]. - The total number of R&D personnel remained at 19, with an increase in average salary from 42.50 million RMB to 58.93 million RMB, reflecting a growth of 38.6%[70]. - The company has a strong R&D team with members recognized as top talents in Beijing, contributing to its innovative capabilities and successful project execution[73]. - The company has implemented an annual training plan that includes various training programs for new and existing employees, utilizing both internal and external resources[174]. Social Responsibility and Environmental Impact - The company invested 1.90 million yuan in environmental protection during the reporting period[189]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[190]. - The company has implemented measures to optimize processes and improve resource utilization to reduce carbon emissions[195]. - The company actively engages in social responsibility, contributing to sustainable economic, social, and environmental development[197]. - The company made a donation of 0.5 million yuan to a school as part of its charitable activities[198]. Future Outlook - The company provided guidance for 2023, expecting revenue to reach between 1.7 billion and 1.8 billion, indicating a growth rate of approximately 13% to 20%[152]. - The company plans to enhance its digital marketing strategy, aiming for a 50% increase in online sales channels[152]. - The company is focusing on expanding new products and markets to effectively increase revenue and profit scales[134]. - The company aims to enhance its core business and expand market presence in 2023, focusing on product development to drive sustained revenue growth[135].